These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36451799)

  • 1. Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast].
    Garrison LP; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8217-8224. PubMed ID: 36451799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast].
    Sullivan SD; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7879-7884. PubMed ID: 36325498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast].
    Drummond MF; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7487-7492. PubMed ID: 36213303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast].
    Devlin NJ; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():7773-7779. PubMed ID: 36263308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast].
    Kanavos PG; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8429-8435. PubMed ID: 36518234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Insider Season 1 Episode 4: How are Costs Measured, and How are CEAs Constructed and Used? (CEA) [Podcast].
    Rutten-van Mölken MPMH; Hartgers-Gubbels ES; Chambers M
    Int J Gen Med; 2022; 15():8055-8061. PubMed ID: 36389024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interview: Health technology assessment in Asia: an emerging trend.
    Yang BM
    J Comp Eff Res; 2012 May; 1(3):221-4. PubMed ID: 24237405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Professor Hassan K. Awwad; The Father of Radiation Oncology and Radiobiology in Egypt and the Arab World, His Good Deeds Last Forever and Inspire us for the Future.
    Zaghloul MS; El-Badawi SA; Abd Elbaky H
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):1-2. PubMed ID: 18839029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamic field of pharmacoeconomics.
    Postma MJ
    Expert Rev Clin Pharmacol; 2009 Mar; 2(2):125-7. PubMed ID: 24410642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese healthcare system: lessons to be learned.
    Ikegami N
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):201-4. PubMed ID: 19527091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
    Kibble A
    Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centenary of the Birth of Academician Prof. Dr. Isak Tadzer, Founder of the Pathophysiology and Nuclear Medicine in Macedonia.
    Karanfilski B
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):9-17. PubMed ID: 28991760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and the quest for preclinical diagnosis: an interview with Professor Werner Poewe.
    Poewe W
    Neurodegener Dis Manag; 2017 Oct; 7(5):273-277. PubMed ID: 29043906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
    Høilund-Carlsen PF
    Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing health through the rapidly developing fields of comparative and cost-effectiveness.
    Annemans L
    J Comp Eff Res; 2012 Nov; 1(6):479-80. PubMed ID: 24236465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of comparative effectiveness research to the future of healthcare evaluation and delivery.
    Lyman GH; Dormer L
    J Comp Eff Res; 2014 Sep; 3(5):455-7. PubMed ID: 25350796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.